狄文，男，主任醫師，教授，副院長，南院常務副院長，醫學博士，博士生導師。1984年畢業于上海醫科大學。上海交通婦產科研究所副所長。上海醫學會婦產科學會主任委員，中華醫學會婦產科學會委員、中華醫學會婦科腫(zhong)(zhong)(zhong)瘤(liu)學(xue)(xue)(xue)會(hui)(hui)委(wei)(wei)員(yuan)，醫師協會(hui)(hui)婦(fu)(fu)產(chan)科(ke)(ke)(ke)分(fen)(fen)會(hui)(hui)常委(wei)(wei)，上(shang)(shang)海市產(chan)科(ke)(ke)(ke)質量控制專(zhuan)員(yuan)會(hui)(hui)委(wei)(wei)員(yuan)。《中(zhong)華(hua)婦(fu)(fu)產(chan)科(ke)(ke)(ke)雜志(zhi)》、《現代婦(fu)(fu)產(chan)科(ke)(ke)(ke)進(jin)展(zhan)》、《實(shi)用婦(fu)(fu)產(chan)科(ke)(ke)(ke)雜志(zhi)》、《中(zhong)華(hua)婦(fu)(fu)幼臨(lin)床(chuang)(chuang)醫學(xue)(xue)(xue)雜志(zhi)》、《國外(wai)醫學(xue)(xue)(xue)-婦(fu)(fu)幼保健分(fen)(fen)冊》編委(wei)(wei)，《實(shi)用婦(fu)(fu)科(ke)(ke)(ke)與產(chan)科(ke)(ke)(ke)雜志(zhi)》、《國外(wai)醫學(xue)(xue)(xue)-計(ji)劃(hua)生育(yu)分(fen)(fen)冊》常務編委(wei)(wei)。七年(nian)(nian)(nian)(nian)制、八年(nian)(nian)(nian)(nian)制醫學(xue)(xue)(xue)教(jiao)(jiao)(jiao)(jiao)(jiao)(jiao)材《婦(fu)(fu)產(chan)科(ke)(ke)(ke)學(xue)(xue)(xue)》編委(wei)(wei)。1998年(nian)(nian)(nian)(nian)狄(di)文(wen)(wen)教(jiao)(jiao)(jiao)(jiao)(jiao)(jiao)授(shou)(shou)(shou)被(bei)入(ru)選 “上(shang)(shang)海市衛(wei)生系統百名跨世紀(ji)學(xue)(xue)(xue)科(ke)(ke)(ke)帶頭人”培養計(ji)劃(hua)。長(chang)期(qi)(qi)從事婦(fu)(fu)產(chan)科(ke)(ke)(ke)臨(lin)床(chuang)(chuang)與基(ji)礎研(yan)究(jiu)(jiu)(jiu)(jiu)，其(qi)(qi)(qi)臨(lin)床(chuang)(chuang)研(yan)究(jiu)(jiu)(jiu)(jiu)涉及領域(yu)廣(guang)泛。早在(zai)(zai)90年(nian)(nian)(nian)(nian)代初期(qi)(qi)，在(zai)(zai)妊(ren)(ren)娠(shen)合(he)并系統性紅斑狼瘡的(de)(de)(de)(de)(de)基(ji)礎和臨(lin)床(chuang)(chuang)研(yan)究(jiu)(jiu)(jiu)(jiu)中(zhong)，打破了SLE婦(fu)(fu)女不(bu)能妊(ren)(ren)娠(shen)的(de)(de)(de)(de)(de)禁(jin)區(qu)，取得(de)(de)(de)了良好(hao)的(de)(de)(de)(de)(de)社(she)會(hui)(hui)和經濟效益，其(qi)(qi)(qi)研(yan)究(jiu)(jiu)(jiu)(jiu)成果(guo)曾(ceng)獲(huo)得(de)(de)(de)上(shang)(shang)海市青(qing)年(nian)(nian)(nian)(nian)科(ke)(ke)(ke)技博(bo)覽會(hui)(hui)銅獎(jiang)，第(di)二屆婦(fu)(fu)產(chan)科(ke)(ke)(ke)青(qing)年(nian)(nian)(nian)(nian)論(lun)文(wen)(wen)二等(deng)(deng)獎(jiang)等(deng)(deng)獎(jiang)項，并通(tong)過了上(shang)(shang)海市組織(zhi)的(de)(de)(de)(de)(de)科(ke)(ke)(ke)技鑒定，醫生們認為其(qi)(qi)(qi)研(yan)究(jiu)(jiu)(jiu)(jiu)達到(dao)國際(ji)先進(jin)水(shui)平。作為上(shang)(shang)海市產(chan)科(ke)(ke)(ke)心(xin)臟病監護中(zhong)心(xin)的(de)(de)(de)(de)(de)成員(yuan)，狄(di)文(wen)(wen)教(jiao)(jiao)(jiao)(jiao)(jiao)(jiao)授(shou)(shou)(shou)在(zai)(zai)妊(ren)(ren)娠(shen)合(he)并心(xin)臟病、心(xin)衰的(de)(de)(de)(de)(de)診治上(shang)(shang)具(ju)有豐(feng)富的(de)(de)(de)(de)(de)臨(lin)床(chuang)(chuang)經驗，心(xin)臟病監護中(zhong)心(xin)吸(xi)引了華(hua)東地區(qu)許(xu)多患嚴核(he)心(xin)臟病的(de)(de)(de)(de)(de)孕婦(fu)(fu)前來就診，有效，中(zhong)心(xin)多次獲(huo)得(de)(de)(de)上(shang)(shang)海市表揚(yang)。狄(di)文(wen)(wen)教(jiao)(jiao)(jiao)(jiao)(jiao)(jiao)授(shou)(shou)(shou)曾(ceng)在(zai)(zai)美(mei)國作為期(qi)(qi)三年(nian)(nian)(nian)(nian)的(de)(de)(de)(de)(de)博(bo)士后(hou)(hou)研(yan)究(jiu)(jiu)(jiu)(jiu)，專(zhuan)攻腫(zhong)(zhong)(zhong)瘤(liu)分(fen)(fen)子生物學(xue)(xue)(xue)研(yan)究(jiu)(jiu)(jiu)(jiu)，其(qi)(qi)(qi)研(yan)究(jiu)(jiu)(jiu)(jiu)成果(guo)“維(wei)甲(jia)酸(suan)感(gan)應(ying)基(ji)因啟動(dong)(dong)子”的(de)(de)(de)(de)(de)研(yan)究(jiu)(jiu)(jiu)(jiu)獲(huo)得(de)(de)(de)1998年(nian)(nian)(nian)(nian)世界(jie)議會(hui)(hui)基(ji)金獎(jiang)。由(you)其(qi)(qi)(qi)領銜的(de)(de)(de)(de)(de)仁濟醫院婦(fu)(fu)產(chan)科(ke)(ke)(ke)腫(zhong)(zhong)(zhong)瘤(liu)小組近年(nian)(nian)(nian)(nian)來在(zai)(zai)婦(fu)(fu)科(ke)(ke)(ke)腫(zhong)(zhong)(zhong)瘤(liu)的(de)(de)(de)(de)(de)綜合(he)診治方(fang)面取得(de)(de)(de)了明顯成績。進(jin)一步(bu)規范和完善了腫(zhong)(zhong)(zhong)瘤(liu)患者的(de)(de)(de)(de)(de)手術(shu)(shu)指征、手術(shu)(shu)方(fang)式(shi)及手術(shu)(shu)后(hou)(hou)的(de)(de)(de)(de)(de)化療方(fang)案(an)，使其(qi)(qi)(qi)5年(nian)(nian)(nian)(nian)生存(cun)率大大提高。狄(di)文(wen)(wen)教(jiao)(jiao)(jiao)(jiao)(jiao)(jiao)授(shou)(shou)(shou)的(de)(de)(de)(de)(de)臨(lin)床(chuang)(chuang)特長(chang)還(huan)包括婦(fu)(fu)產(chan)科(ke)(ke)(ke)感(gan)染性疾病、子宮內(nei)膜異(yi)位癥、宮頸疾病及妊(ren)(ren)娠(shen)合(he)并癥等(deng)(deng)。科(ke)(ke)(ke)研(yan)上(shang)(shang)，目(mu)前承擔(dan)自然(ran)基(ji)金項目(mu)級多項市級以(yi)上(shang)(shang)科(ke)(ke)(ke)研(yan)課(ke)題，內(nei)容涉及婦(fu)(fu)科(ke)(ke)(ke)腫(zhong)(zhong)(zhong)瘤(liu)的(de)(de)(de)(de)(de)發(fa)病機理，腫(zhong)(zhong)(zhong)瘤(liu)化療的(de)(de)(de)(de)(de)耐藥機制及腫(zhong)(zhong)(zhong)瘤(liu)治療的(de)(de)(de)(de)(de)新方(fang)法等(deng)(deng)。在(zai)(zai)雜志(zhi)發(fa)表論(lun)文(wen)(wen)100余篇,主(zhu)編、參編專(zhuan)著十余部。作為上(shang)(shang)海交通(tong)大學(xue)(xue)(xue)教(jiao)(jiao)(jiao)(jiao)(jiao)(jiao)授(shou)(shou)(shou)，在(zai)(zai)教(jiao)(jiao)(jiao)(jiao)(jiao)(jiao)學(xue)(xue)(xue)上(shang)(shang)，強調授(shou)(shou)(shou)與漁的(de)(de)(de)(de)(de)教(jiao)(jiao)(jiao)(jiao)(jiao)(jiao)學(xue)(xue)(xue)方(fang)式(shi)，充(chong)(chong)分(fen)(fen)發(fa)揮學(xue)(xue)(xue)生的(de)(de)(de)(de)(de)主(zhu)觀能動(dong)(dong)性，并且充(chong)(chong)分(fen)(fen)利用其(qi)(qi)(qi)淵博(bo)的(de)(de)(de)(de)(de)婦(fu)(fu)產(chan)科(ke)(ke)(ke)學(xue)(xue)(xue)知識及時將研(yan)究(jiu)(jiu)(jiu)(jiu)進(jin)展(zhan)帶入(ru)課(ke)堂(tang)。狄(di)文(wen)(wen)教(jiao)(jiao)(jiao)(jiao)(jiao)(jiao)授(shou)(shou)(shou)科(ke)(ke)(ke)學(xue)(xue)(xue)的(de)(de)(de)(de)(de)教(jiao)(jiao)(jiao)(jiao)(jiao)(jiao)學(xue)(xue)(xue)方(fang)法，生動(dong)(dong)的(de)(de)(de)(de)(de)教(jiao)(jiao)(jiao)(jiao)(jiao)(jiao)學(xue)(xue)(xue)方(fang)式(shi)及新穎的(de)(de)(de)(de)(de)教(jiao)(jiao)(jiao)(jiao)(jiao)(jiao)學(xue)(xue)(xue)內(nei)容深受學(xue)(xue)(xue)生的(de)(de)(de)(de)(de)歡迎，1999年(nian)(nian)(nian)(nian)被(bei)評為上(shang)(shang)海市高校青(qing)年(nian)(nian)(nian)(nian)教(jiao)(jiao)(jiao)(jiao)(jiao)(jiao)師。2005年(nian)(nian)(nian)(nian)榮獲(huo)“寶鋼教(jiao)(jiao)(jiao)(jiao)(jiao)(jiao)師獎(jiang)”。發(fa)表論(lun)文(wen)(wen)： (1) Cao C, Lu S, Sowa A, Kivlin R, Amaral A, Chu W, Yang H, Di W, Wan Y.Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.Cancer Letters.2008,266: 249–262. (2) Ji C, Cao C, Lu S, Kivlin R, Amaral A, Kouttab N, Yang H, Chu W, Bi Z, Di W, Wan Y.Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells.Cancer Chemother Pharmacol.2008 Oct;62(5):857-65. (3) Di W, Guo SW. The search for genetic variants predisposing women to endometriosis.Curr Opin Obstet Gynecol. 2007 Aug;19(4):395-401. Review. (4) Related Articles, LinksQiu L, Zhou C, Sun Y, Di W, Scheffler E, Healey S, Kouttab N, Chu W, Wan Y.Crosstalk between EGFR and TrkB enhances ovarian cancer cell migration and proliferation.Int J Oncol. 2006 Oct;29(4):1003-11. (5) Qiu L, Zhou C, Sun Y, Di W, Scheffler E, Healey S, Wanebo H, Kouttab N, Chu W, Wan Y.Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells.Oncol Rep. 2006 Oct;16(4):907-13. (6) Zhang S, Lin QD, DI W. Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1.Int J Gynecol Cancer. 2006 Mar-Apr;16(2):522-31. (7) Qiu L, Di W, Jiang Q, Scheffler E, Derby S, Yang J, Kouttab N, Wanebo H, Yan B, Wan Y. Inhibition of EGFR/PI13/AKT cell survival pathway promotes TSA’s effect on cell death and migration in human ovarian cancer cells.Int J Oncol. 2006 Jul;29(1):269-78. (8) Qiu L, Di W, Jiang Q, Scheffler E, Derby S, Yang J, Kouttab N, Wanebo H, Yan B, Wan Y.Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death.Int J Oncol. 2005 Nov;27(5):1441-8. (9) Qiu L, Wang Q, Di W, Jiang Q, Schefeller E, Derby S, Wanebo H, Yan B, Wan Y.Transient activation of EGFR/AKT cell survival pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid.Int J Oncol. 2005 Sep;27(3):823-30. (10) Wang X, Lin Q, Ma Z, Hong Y, Zhao A, Di W, Lu P.Association of the A/G polymorphism at position 49 in exon 1 of CTLA-4 with the susceptibility to unexplained recurrent spontaneous abortion in the Chinese population.Am J Reprod Immunol. 2005 Feb;53(2):100-5. (11) Wang X, Huang Z, Di W, Lin Q. Comparison of D&C and hysterectomy pathologic findings in endometrial cancer patients.Arch Gynecol Obstet. 2005 Jul;272(2):136-41